Evidence map›Paper›PMID 42222586›Full record

ArticleOphthalmology science2026

Prospective Data Curation Enables High-Performance Artificial Intelligence for Diabetic Retinopathy Screening in a Resource-Limited Setting.

Cameron M Ashrafzadeh, Milan Bahi, Amira Mostafa, Mostafa El Manhaly, Mohamed Ghoneim, Bassma Al-Bayoumy, Enas Khamis, Merna Mostafa, Heba Abdel Aziz, Nadine Khaled and 4 more

Abstract read
In one paragraph

Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cameron M AshrafzadehBeetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Milan BahiBeetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Amira MostafaAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Mostafa El ManhalyAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Mohamed GhoneimAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Bassma Al-BayoumyAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Enas KhamisAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Merna MostafaAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Heba Abdel AzizAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Nadine KhaledAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Ahmed SoukaAlexandria iCare Retina Reading Center, Alexandria, Egypt.
Paolo S SilvaBeetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Lloyd Paul AielloBeetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.
Mohamed AshrafBeetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To determine whether a high-quality, prospectively curated dataset can, by itself, enable the development of robust and clinically effective artificial intelligence as a medical device (AIaMD) models for diabetic retinopathy (DR) screening, even with minimal artificial intelligence (AI) infrastructure. This study evaluates whether careful data curation, standardized acquisition, and rigorous grading processes can yield high-performing AI models for more-than-mild DR (MTM) and diabetic macular edema (DME) detection from ultra-widefield (UWF) fundus images. Design: An evaluation of diagnostic technology. Subjects: Patients with diabetes receiving imaging at Alexandria iCare Retina Reading Center. Methods: A total of 152 025 UWF color images were collected between February 2022 and June 2024 at a UWF image reading center during routine screening. This was a cross-sectional study with patient consent obtained at the time of imaging. After excluding noncolor or ungradable images, 26 232 UWF color images from 5394 diabetic patients were used to train 2 Inception V3-based convolutional neural networks: one to detect MTM and another for OCT-confirmed DME. Images were split 80:10:10 by patient into training, validation, and test sets. Models were trained on red-green channel inputs using standard augmentation and Adam optimization (learning rate 0.0005). Prospective validation was performed on 12 698 additional images from 3096 patients collected between July and December 2024, following identical imaging and adjudication protocols. Main Outcome Measures: Area under the curve (AUC), sensitivity, and specificity. Results: In baseline testing, the MTM model achieved an AUC of 0.962 ± 0.003, sensitivity of 0.922 ± 0.001, and specificity of 0.873 ± 0.010; the DME model achieved an AUC of 0.879 ± 0.014, sensitivity of 0.809 ± 0.022, and specificity of 0.790 ± 0.023. In the prospective dataset, the MTM model maintained strong performance (AUC 0.949; sensitivity 0.86-0.89; specificity 0.85-0.89), while the DME model yielded an AUC of 0.821 with balanced sensitivity (0.76) and specificity (0.73). Gradient-weighted class activation mapping visualizations confirmed focus on clinically relevant lesions. Conclusions: This study demonstrates that rigorous prospective data collection and quality control can produce high-performing AIaMDs even with limited AI engineering resources. Locally curated datasets aligned with regional populations, equipment, and workflows can yield reliable, regulation-ready tools that advance equitable DR screening in resource-limited settings. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Indexed as

Artifical IntelligenceDiabetic macular edemaDiabetic RetinopathyScreening

Identifiers

PMID42222586
PMCPMC13218245

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.